Latent Autoimmune Diabetes in Adults

  title={Latent Autoimmune Diabetes in Adults},
  author={M. Landin-Olsson},
  journal={Annals of the New York Academy of Sciences},
  • M. Landin-Olsson
  • Published 1 April 2002
  • Medicine, Biology
  • Annals of the New York Academy of Sciences
Abstract: Latent autoimmune diabetes in adults (LADA) is a special form of diabetes that is clinically similar to type 2 diabetes but with positivity for pancreatic autoantibodies. The frequency of LADA patients among all patients diagnosed as type 2 varies between 6‐50% in various populations. The frequency is higher in younger age groups. It is clear, however, that the frequency of autoimmune diabetes among adults is underestimated. Clinical features such as age and severity of symptoms are… 

Latent autoimmune diabetes in adults: definition, prevalence, beta-cell function, and treatment.

Latent autoimmune diabetes in adults (LADA) is a disorder in which, despite the presence of islet antibodies at diagnosis of diabetes, the progression of autoimmune beta-cell failure is slow. LADA

Detection of Latent Autoimmune Diabetes of Adults among Type 2 Diabetic Patients Using Glutamic Acid Decarboxylase Antibodies

Assessment of the prevalence of LADA among type 2 diabetic patients using glutamic acid decarboxylase (GAD) antibodies found 14 patients (14%) were positive for GADA, accounting for 14% of T2DM using GADA assay.

Latent autoimmune diabetes in adults (LADA)

Cpeptide and autoimmunemarkers are important for a correct classification of DM diagnosed in group 30-50 years, and are useful for proper classification and early adequate treatment.

Latent Autoimmune Diabetes of Adult Masquerading as Type 2 Diabetes Mellitus

It is important to identify LADA in adult patients thought to have T2DM, as these patients respond poorly to oral hypoglycemic drug therapy, require insulin and are at increased risk for developing ketoacidosis.

Type 1 Diabetes-related Autoantibodies in Different Forms of Diabetes.

Autoantibodies against Glutamic Acid Decarboxylase (GADA), insulinoma antigen-2 (IA- 2A), insulin (IAA) and the most recently Zinc Transporter 8 (ZnT8A) are today the only biomarkers that can distinguish Latent Autoimmune Diabetes in Adults (LADA) from phenotypically type 2 diabetes.

Diabetes mellitus in Adults - Aspects of Incidence, Autoimmunity and C-peptide

Adult type 1 patients with long duration with new onset diabetes were examined for pancreatic antibodies, residual C-peptide, and other autoantibodies and complications, with focus on complications from the connective tissues.

Slow-progression, autoimmune, type 1 diabetes in adults: a cause of failure of resolution of diabetes after bariatric surgery.

  • M. Deitel
  • Medicine
    Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery
  • 2009

Latent autoimmune diabetes of adults (LADA).

Study of some inflammatory proteins and autoantibodies in diabetes mellitus type II patients in Baghdad.

The results show a significant increasing serum ceruloplasmin level with non-significant decreasing level of Transferrin in patient group in comparison with control and the same patients show a positive result for autoantibodies that may refer to inflammatory aspects of disease associated with autoimmunity markers.



Progress in the characterization of slowly progressive autoimmune diabetes in adult patients (LADA or type 1.5 diabetes).

The relatively low antibody titers against islet-cell antigens in LADA patients may be sign of a less aggressive form of autoimmune diabetes and could be responsible for the long non-insulin requirement phase of this diabetes type.

Evidence of islet cell autoimmunity in elderly patients with type 2 diabetes.

In type 2 diabetic subjects > or =65 years old, the presence of islet cell autoimmunity is associated with an impairment of the acute-phase insulin secretion, as revealed by an OGTT.

Latent Autoimmune Diabetes Mellitus in Adults (LADA): the Role of Antibodies to Glutamic Acid Decarboxylase in Diagnosis and Prediction of Insulin Dependency

Testing for anti‐GAD in adult‐onset non‐obese diabetic patients should be a routine procedure in order to detect latent insulin‐dependency at the earliest possible stage, since this assay can assist in the correct classification of diabetes, and more appropriate therapy.

Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies.

GADab+ patients differ from both GADab- type 2 diabetic patients and type 1 diabetic patients with respect to beta-cell function, features of the metabolic syndrome, and type1 diabetes susceptibility genes, and it is proposed that LADA be defined as GADAB positivity (>5 relative units) in patients older than 35 years at onset of type 2 diabetes.

Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA)

The combination of ICA and Gad antibodies and high titre of GAD antibodies are characteristic of patients with insulin deficiency with the clinical features of Type I (insulin-dependent) diabetes mellitus (LADA-type 1).

Clinical characteristics of patients with the initial diagnosis of NIDDM with positivity for antibodies to glutamic acid decarboxylase.

Clinical characteristics of patients with non-insulin-dependent diabetes mellitus who were positive for GAD-Ab differed significantly from those of the patients negative for this enzyme.

Combinations of Beta Cell Specific Autoantibodies at Diagnosis of Diabetes in Young Adults Reflects Different Courses of Beta Cell Damage

It is concluded that young adult diabetic patients positive only for ICA at diagnosis have a better preserved beta cell function with higher levels of C-peptide during the first three years compared with patients positive for GADA alone or in combinations with other autoantibodies.

Clinical evaluation of non-insulin-dependent diabetes mellitus patients with autoantibodies to glutamic acid decarboxylase.

The results suggest that the presence of both GAD-Ab and ICAs represents a high risk for IDDM in G AD-Ab+ NIDDM patients.

Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1(1/2) diabetes in patients presenting with type 2 diabetes.

It is concluded that screening with antibodies, mainly ICA and GAD, but not age, BMI, or clinical presentation should be used to identify type 1(1/2) diabetes.